XOMA Corporation (Nasdaq: XOMA) reported its first quarter 2021
financial results and provided a recent operations update.
“Our team continues to identify exciting assets to add to our
milestone and royalty portfolio. Their efforts resulted in
our acquisition of two economic licenses from Viracta during the
first quarter. We were delighted to add Day One
Biopharmaceuticals’ DAY101 (pan-RAF kinase inhibitor) and Denovo
Biopharma’s vosaroxin (topoisomerase II inhibitor) to our growing
list of partner-funded assets,” stated Jim Neal, Chief Executive
Officer of XOMA. “I am proud that our team continues to be
productive in this COVID-impacted environment.
“In addition, since the close of the first quarter, we added
three clinical-stage assets to our portfolio, AFM13, AFM24, and an
undisclosed asset, each of which resulted from a research and
discovery license agreement we established with Affimed fifteen
years ago. These are three interesting oncology assets as
they are designed to activate the body’s innate immune system to
kill cancer cells. We believe the initial data from the AFM13
Phase 1 study in patients with relapsed/refractory CD30+ lymphomas,
recently presented at the AACR Virtual Annual Meeting, are
encouraging. This week, we received notification from Janssen
that the first patient has been dosed in the inaugural cetrelimab
Phase 3 clinical study, making it the second molecule in our
portfolio to advance to the final stage of clinical
development.
“To continue to support our strategy to expand our potential
milestone and royalty portfolio via acquisition transactions, in
April we completed a $40 million offering of Series B Perpetual
Preferred Stock, which pays an 8.375% dividend, bringing our cash
and restricted cash to over $100 million. And finally, we
paid our first dividend on the Series A Perpetual Preferred
Stock. Today, we have one of the strongest financial
positions in our recent history, particularly when coupled with our
very lean expense structure.”
Financial ResultsXOMA recorded total revenues
of $0.4 million for the first quarter of 2021, compared to $0.8
million for the first quarter of 2020. The decrease for the
three months ended March 31, 2021, as compared to the same period
in 2020, was primarily due to $0.5 million in revenue recognized in
the first quarter of 2020 related to a milestone event under XOMA’s
license agreement with Compugen.
Research and development expenses were $0.1 million for the
first quarter of 2021, compared to $0.1 million for the first
quarter of 2020.
General and administrative (“G&A”) expenses were $6.7
million for the first quarter of 2021, compared to $6.4 million for
the first quarter of 2020. The increase of $0.3 million for
the three months ended March 31, 2021, as compared to the same
period of 2020, was primarily due to a $1.4 million increase in
salary and related expenses (including an increase of $1.1 million
in non-cash stock compensation expense) and $0.3 million increase
in consulting and deal costs, partially offset by a $1.4 million
decrease in bad debt expense.
In the first quarter of 2021, G&A expenses included $2.9
million in stock-based compensation expense compared with $1.8
million in the corresponding quarter of 2020. The increase in
expense was primarily due to an increase in the fair value of
options granted driven by an increase in our stock price. In
the first quarter of 2020, non-cash G&A expenses also included
$1.4 million in bad debt expense. The Company’s net cash used
in operations in the first quarter of 2021 was $0.9 million, as
compared with $2.3 million during the first quarter of 2020.
In the first quarter of 2021, XOMA recorded $0.3 million in
total interest expense, as compared to $0.5 million in the
corresponding period of 2020, both of which reflect the Company’s
outstanding loan balances with Silicon Valley Bank and
Novartis.
For the quarter ended March 31, 2021, XOMA recorded total other
expense of $0.7 million, which included a $0.7 million change in
the fair value of equity securities. For the quarter ended
March 31, 2020, XOMA reported total other expense of $0.1 million,
which included a $0.3 million change in the fair value of equity
securities offset by $0.1 million in investment
income.
In the first quarter of 2020, XOMA recorded an income tax
benefit of $1.5 million as a result of a provision regarding net
operating loss carrybacks within the CARES Act.
Net loss for the first quarter of 2021 was $7.4 million,
compared to net loss of $4.8 million for the first quarter of
2020.
On March 31, 2021, XOMA had cash of $67.8 million. The
Company ended December 31, 2020, with cash of $84.2 million. On
April 12, 2021, XOMA announced the closing of its Depositary Shares
Offering and the exercise of the underwriters’ option, which
resulted in approximately $38.0 million after deducting
underwriting discounts and commissions, but before expenses.
On April 15, 2021, the Company paid its first dividend on Series A
Cumulative Perpetual Preferred (Nasdaq: XOMAP) in the amount of
$0.71875 per share. The Company continues to believe its
current cash position will be sufficient to fund XOMA’s operations
for multiple years.
About XOMA CorporationXOMA is a biotechnology
royalty aggregator playing a unique role in helping biotech
companies achieve their goal of improving human health. XOMA
acquires the potential future economics associated with
pre-commercial therapeutic candidates that have been licensed to
pharmaceutical or biotechnology companies. When XOMA acquires
the future economics, the seller receives non-dilutive,
non-recourse funding they can use to advance their internal drug
candidate(s) or for general corporate purposes. The Company
has an extensive and growing portfolio with more than 70 assets
(asset defined as the right to receive potential future economics
associated with the advancement of an underlying therapeutic
candidate). For more information about the Company and its
portfolio, please visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
creating additional value for the stockholders, cash sufficiency
forecast, economic outlook, and potential impact of the COVID-19
pandemic. These statements are based on assumptions that may
not prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry, including those related to the fact that
our product candidates subject to out-license agreements are still
being developed, and our licensees may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; if
the therapeutic product candidates to which we have a royalty
interest do not receive regulatory approval, our third-party
licensees will not be able to market them, and the impact to the
global economy as a result of the COVID-19 pandemic. Other
potential risks to XOMA meeting these expectations are described in
more detail in XOMA's most recent filing on Form 10-K and in other
SEC filings. Consider such risks carefully when considering
XOMA's prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward-looking statement, except as required by
applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
As of the date of this press release, all assets in XOMA’s
milestone and royalty portfolio are investigational
compounds. Efficacy and safety have not been
established. There is no guarantee that any of these assets
will become commercially available.
XOMA
CORPORATION |
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS |
|
(unaudited) |
|
(in
thousands, except per share amounts) |
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
|
March 31, |
|
|
|
2021 |
|
|
|
2020 |
|
|
Revenues: |
|
|
|
|
Revenue from contracts with customers |
$ |
19 |
|
|
$ |
500 |
|
|
Revenue recognized under units-of-revenue
method |
|
356 |
|
|
|
304 |
|
|
Total
revenues |
|
375 |
|
|
|
804 |
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
Research and development |
|
61 |
|
|
|
62 |
|
|
General and administrative |
|
6,741 |
|
|
|
6,358 |
|
|
Total
operating expenses |
|
6,802 |
|
|
|
6,420 |
|
|
|
|
|
|
|
Loss from
operations |
|
(6,427 |
) |
|
|
(5,616 |
) |
|
|
|
|
|
|
Other income
(expense), net: |
|
|
|
|
Interest
expense |
|
(289 |
) |
|
|
(542 |
) |
|
Other
expense, net |
|
(657 |
) |
|
|
(126 |
) |
|
Loss before
income tax |
|
(7,373 |
) |
|
|
(6,284 |
) |
|
Income tax
benefit |
|
— |
|
|
|
1,526 |
|
|
|
|
|
|
|
Net loss and
comprehensive loss |
$ |
(7,373 |
) |
|
$ |
(4,758 |
) |
|
Less: Series
A accumulated dividends |
|
(530 |
) |
|
|
— |
|
|
Net loss
available to common stockholders, basic and diluted |
$ |
(7,903 |
) |
|
$ |
(4,758 |
) |
|
Basic and
diluted net loss per share available to common stockholders |
$ |
(0.70 |
) |
|
$ |
(0.49 |
) |
|
Weighted
average shares used in computing basic and diluted net loss per
share available to common stockholders |
|
11,240 |
|
|
|
9,761 |
|
|
|
|
|
|
|
XOMA
CORPORATION |
|
CONDENSED
CONSOLIDATED BALANCE SHEETS |
|
(unaudited) |
|
(in
thousands, except share and per share amounts) |
|
|
|
|
|
|
|
|
|
March
31, |
|
December 31, |
|
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
Current
assets: |
|
|
|
|
|
Cash |
|
$ |
67,808 |
|
|
$ |
84,222 |
|
|
Restricted cash |
|
|
2,142 |
|
|
|
1,611 |
|
|
Trade and other receivables, net |
|
|
80 |
|
|
|
263 |
|
|
Income tax receivable |
|
|
— |
|
|
|
1,526 |
|
|
Prepaid expenses and other current assets |
|
|
218 |
|
|
|
443 |
|
|
Total current assets |
|
|
70,248 |
|
|
|
88,065 |
|
|
Long-term
restricted cash |
|
|
— |
|
|
|
531 |
|
|
Property and
equipment, net |
|
|
19 |
|
|
|
21 |
|
|
Operating
lease right-of-use assets |
|
|
320 |
|
|
|
359 |
|
|
Long-term
royalty receivables |
|
|
48,075 |
|
|
|
34,575 |
|
|
Equity
securities |
|
|
1,021 |
|
|
|
1,693 |
|
|
Other
assets |
|
|
210 |
|
|
|
41 |
|
|
Total assets |
|
$ |
119,893 |
|
|
$ |
125,285 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
Accounts payable |
|
$ |
671 |
|
|
$ |
456 |
|
|
Accrued and other liabilities |
|
|
1,376 |
|
|
|
642 |
|
|
Contingent consideration under royalty purchase agreements |
|
|
75 |
|
|
|
75 |
|
|
Operating lease liabilities |
|
|
183 |
|
|
|
179 |
|
|
Unearned revenue recognized under units-of-revenue method |
|
|
1,482 |
|
|
|
1,452 |
|
|
Contingent liabilities |
|
|
1,410 |
|
|
|
1,410 |
|
|
Current portion of long-term debt |
|
|
7,201 |
|
|
|
8,088 |
|
|
Preferred stock dividend accrual |
|
|
707 |
|
|
|
— |
|
|
Total current liabilities |
|
|
13,105 |
|
|
|
12,302 |
|
|
Unearned
revenue recognized under units-of-revenue method – long-term |
|
|
13,130 |
|
|
|
13,516 |
|
|
Long-term
debt |
|
|
11,654 |
|
|
|
12,764 |
|
|
Long-term
operating lease liabilities |
|
|
182 |
|
|
|
229 |
|
|
Other
liabilities – long-term |
|
|
102 |
|
|
|
50 |
|
|
Total liabilities |
|
|
38,173 |
|
|
|
38,861 |
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
Preferred Stock, $0.05 par value, 1,000,000 shares authorized: |
|
|
|
|
|
8.625% Series A cumulative, perpetual preferred stock, 984,000
shares issued and outstanding at March 31, 2021 and December 31,
2020 |
|
|
49 |
|
|
|
49 |
|
|
Convertible preferred stock, 5,003 shares issued and outstanding at
March 31, 2021 and December 31, 2020 |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.0075 par value, 277,333,332 shares authorized,
11,259,926 and 11,228,792 shares issued and outstanding at March
31, 2021 and December 31, 2020, respectively |
|
|
84 |
|
|
|
84 |
|
|
Additional paid-in capital |
|
|
1,270,046 |
|
|
|
1,267,377 |
|
|
Accumulated deficit |
|
|
(1,188,459 |
) |
|
|
(1,181,086 |
) |
|
Total stockholders’ equity |
|
|
81,720 |
|
|
|
86,424 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
119,893 |
|
|
$ |
125,285 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor contacts: Gitanjali Jain
Solebury Trout
+1-646-378-2949
gogawa@soleburytrout.com
Juliane SnowdenXOMA+1-646-438-9754juliane.snowden@xoma.com
Media contact: Kathy Vincent KV
Consulting & Management +1-310-403-8951
kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024